GLP-1 receptor agonists reduced stroke risk by 33% compared to SGLT2 inhibitors in a massive retrospective analysis of 195,072 Veterans with type 2 diabetes. The hazard ratio of 0.67 represents a substantial protective effect that held consistent across ischemic and hemorrhagic strokes, all age groups, kidney disease stages, and blood sugar control levels. This finding adds crucial evidence to the growing body of research demonstrating cardiovascular benefits of GLP-1 drugs like semaglutide and liraglutide beyond their diabetes management effects. While both medication classes offer proven benefits for diabetic patients, this comparison suggests meaningful differences in stroke prevention capabilities. The large veteran population provides robust statistical power, though the retrospective design limits causal inferences. Additionally, veteran demographics may not fully represent broader populations, particularly regarding gender and healthcare access patterns. As this is a preprint awaiting peer review, these promising results require validation through the formal review process. If confirmed, this could influence clinical decision-making for diabetes treatment selection, especially in patients with elevated stroke risk factors.